BACKGROUND: Optimizing the validity and responsiveness of utility measures will enhance their usefulness in randomized trials. We evaluated the impact of clinical marker state (CMS) rating prior to patients' rating their own health on two utility instruments (feeling thermometer (FT) and standard gamble (SG)) in patients with chronic respiratory disease (CRD). METHODS: We randomized 182 patients with CRD to complete the FT (self-administered) andSG with CMS (FT+/SG+, n=91) or without marker states (FT-/SG-, n=91) before and after undergoing respiratory rehabilitation in a multi-center trial. RESULTS: Use of CMS did not influence baseline utility scores. Improvement after therapy on the scale from 0 (dead) to 1.0 (full health) was 0.04 both in FT+ (p=0.03) and FT- (p=0.02; the difference between FT+ and FT- was 0.00, p=0.83). Improvement on the SG was 0.05 in both SG+ (p=0.08) and SG- (p=0.04; difference between SG+ and SG- 0.00, p=0.95). Correlations with other health related quality of life scores were highest for FT+. CONCLUSION: Administration of CMS did not improve responsiveness of the FT but may have improved construct validity. The SG showed limited construct validity and responsiveness that was not influenced by CMS use.
RCT Entities:
BACKGROUND: Optimizing the validity and responsiveness of utility measures will enhance their usefulness in randomized trials. We evaluated the impact of clinical marker state (CMS) rating prior to patients' rating their own health on two utility instruments (feeling thermometer (FT) and standard gamble (SG)) in patients with chronic respiratory disease (CRD). METHODS: We randomized 182 patients with CRD to complete the FT (self-administered) and SG with CMS (FT+/SG+, n=91) or without marker states (FT-/SG-, n=91) before and after undergoing respiratory rehabilitation in a multi-center trial. RESULTS: Use of CMS did not influence baseline utility scores. Improvement after therapy on the scale from 0 (dead) to 1.0 (full health) was 0.04 both in FT+ (p=0.03) and FT- (p=0.02; the difference between FT+ and FT- was 0.00, p=0.83). Improvement on the SG was 0.05 in both SG+ (p=0.08) and SG- (p=0.04; difference between SG+ and SG- 0.00, p=0.95). Correlations with other health related quality of life scores were highest for FT+. CONCLUSION: Administration of CMS did not improve responsiveness of the FT but may have improved construct validity. The SG showed limited construct validity and responsiveness that was not influenced by CMS use.
Authors: Holger J Schünemann; Lauren Griffith; Roman Jaeschke; Roger Goldstein; David Stubbing; Gordon H Guyatt Journal: J Clin Epidemiol Date: 2003-12 Impact factor: 6.437
Authors: Milo A Puhan; Gordon H Guyatt; Victor M Montori; Mohit Bhandari; P J Devereaux; Lauren Griffith; Roger Goldstein; Holger J Schünemann Journal: J Clin Epidemiol Date: 2005-05 Impact factor: 6.437
Authors: Wojtek Wiercioch; Robby Nieuwlaat; Elie A Akl; Robert Kunkle; Kendall E Alexander; Adam Cuker; Anita Rajasekhar; Pablo Alonso-Coello; David R Anderson; Shannon M Bates; Mary Cushman; Philipp Dahm; Gordon Guyatt; Alfonso Iorio; Wendy Lim; Gary H Lyman; Saskia Middeldorp; Paul Monagle; Reem A Mustafa; Ignacio Neumann; Thomas L Ortel; Bram Rochwerg; Nancy Santesso; Sara K Vesely; Daniel M Witt; Holger J Schünemann Journal: Blood Adv Date: 2020-05-26
Authors: Zoran Kvrgic; Gladys B Asiedu; Cynthia S Crowson; Jennifer L Ridgeway; John M Davis Journal: Arthritis Care Res (Hoboken) Date: 2018-09-04 Impact factor: 4.794
Authors: Pablo Alonso-Coello; Shanil Ebrahim; Gordon H Guyatt; Kari A O Tikkinen; Mark H Eckman; Ignacio Neumann; Sarah D McDonald; Elie A Akl; Shannon M Bates Journal: BMC Pregnancy Childbirth Date: 2012-05-30 Impact factor: 3.007